Aurobindo Pharma, the fourth largest pharma company in India with net sales of Rs.12,000 crore plus, has posted small growth of 4.1 per cent in its consolidated net profit to due to forex loss and higher input cost. Its consolidated net profit increased to Rs.432 crore during the first quarter ended June 2015 from Rs.415 crore in the corresponding quarter of last year. Its forex loss amounted to Rs.25.58 crore as against gain of Rs.1.42 crore. Its tax provision went up by 28.1 per cent to Rs.187 crore from Rs.146 crore.

EBDITA worked out to Rs.754 crore as against Rs.669 crore due to higher other operating income as well as other income. Its other income increased to Rs.29.11 crore from Rs.10.81 crore and other operating income by 24.4 per cent to Rs.57 crore from Rs.16 crore. Its EPS improved to R 14.81 from Rs.14.25 in the last period. The board of directors has declared an interim dividend of 50 per cent for the year 2015-16.

Its net sales improved by 12.8 per cent to Rs.3,264 crore from Rs.2,895 crore. Aurobindo's formulation sales increased by 15.9 per cent to Rs.2,637 crore and APIs sales by 7.9 per cent to Rs.723 crore. Formulation sales constitute 78.5 per cent and API 21.5 per cent of gross sales. Its formulations sales in USA increased by 28.1 per cent to Rs.1,430 crore from Rs.1,116 crore in the similar period of last year. However, its sales in Europe declined by 7.1 per cent to Rs.742 crore from Rs.798 crore. Its sales in ROW improved by 24.6 per cent to Rs.171 crore from Rs.137 crore.

Aurobindo's export improved by 11.2 per cent to Rs.1,777 crore from Rs.1,598 crore and its domestic sales improved by 24.3 per cent to Rs.482 crore from Rs.388 crore.

N Govindarajan, managing director said, We are pleased to initiate the year with broad based growth across most business verticals. We continue on our efforts towards higher degree of differentiation including specialty generics and active pharmaceutical.”

The company has filed 3 ANDAs and 4 DMFs during the quarter under review, taking cumulative filings to 379 ANDAs and 196 DMFs. The total approvals from US FDA reached at 201 ANDAs and 72 in Canada. It also filed 53 formulations dossiers and 27 API DMFs in other key advanced market and its total reached at 2,237 dossiers and 2,423 DMFs as at the end of June 2015.